|Over a week ago|
Ultragenyx resumed with an In Line at Evercore ISI » 16:3511/2311/23/20
Evercore ISI analyst…
Evercore ISI analyst Liisa Bayko resumed coverage of Ultragenyx with an In Line rating and $110 price target. She thinks Ultragenyx has a "solid long-term outlook," but with shares up 170% year-to-date she thinks the company's guidance of growth to "approaching $1B" by 2025 is already reflected in the current valuation. She views 2021 as "more of an execution year with few pipeline catalysts," Bayko added.
Barclays to hold a virtual summit » 08:4711/1611/16/20
BLUE, PTCT, RARE, QURE, RGNX, MGTX, ORTX, SGMO, EDIT, NTLA
Gene Editing & Gene…
Gene Editing & Gene Therapy Virtual Summit to be held on November 16.
Ultragenyx downgraded to Neutral from Buy at BofA » 08:0411/1211/12/20
BofA analyst Tazeen Ahmad…
BofA analyst Tazeen Ahmad downgraded Ultragenyx to Neutral from Buy with a price target of $126, up from $104. While Ahmad sees the company having "a solid revenue-generating portfolio" with Crysvita and Dojolvi, the shares now look fairly valued as updates on pipeline opportunities are awaited, the analyst contends.
Ultragenyx to build large-scale gene therapy manufacturing facility » 09:0311/0911/09/20
Ultragenyx Pharmaceutical announced that it plans to build a new large-scale gene therapy manufacturing facility in Bedford, Massachusetts. The new facility will enable in-house manufacturing of the Company's pipeline of clinical stage adeno-associated virus (AAV)- based gene therapies, including DTX301 for ornithine transcarbamylase (OTC) deficiency, DTX401 for glycogen storage disease type Ia (GSDIa), and UX701 for Wilson disease, as well as other preclinical programs. The company will continue to leverage some contract manufacturing organizations in addition to its own manufacturing facility. Ultragenyx will use both of its gene therapy manufacturing platforms at the new facility: the HeLa producer cell line (PCL) platform which enables large 2,000 liter commercial-scale manufacturing and yields high-quality product from a highly reproducible, highly scalable platform, and the Company's HEK293 transient transfection system. The planned Phase I facility will encompass 100,000 square feet and provide important internal capacity to develop and manufacture supply of Ultragenyx's gene therapies for both clinical stage and approved products. The facility will be able to support two independent manufacturing suites with a capacity of 30 runs per year. Construction of the new facility has begun and is expected to be complete in 2023. As the facility becomes fully operational, Ultragenyx expects to hire approximately 100 to 150 full-time employees, over a five-year period across a broad range of functions and skill sets, adding to their existing base of employees in Massachusetts. Ultragenyx already controls land and development rights for an additional 86,000 square feet of Phase II expansion on-site which could be used to double capacity if needed.
|Over a month ago|
Ultragenyx 4.44M share Secondary priced at $90.00 » 19:0810/2810/28/20
The deal priced below the…
The deal priced below the last closing price of $95.00. JPMorgan, Goldman Sachs, BofA and Cowen are acting as joint book running managers for the offering.
Ultragenyx price target raised to $105 from $97 at Wedbush » 08:5410/2810/28/20
Wedbush analyst Laura…
Wedbush analyst Laura Chico raised the firm's price target on Ultragenyx to $105 from $97 and keeps an Outperform rating on the shares. The analyst notes the Q3 update was largely as anticipated with continued Crysvita execution. Chico continues to anticipate steady uptake as additional geographies come online, as well as the TIO indication. She also looks ahead to the GTX-102 update in December to better understand the Angelman syndrome candidate's efficacy profile. The Ultragenyx development pipeline "bench" remains deep and Chico sees the optionality it provides as a unique strength.
Ultragenyx price target raised to $115 from $110 at SVB Leerink » 08:4710/2810/28/20
SVB Leerink analyst…
SVB Leerink analyst Joseph Schwartz raised the firm's price target on Ultragenyx to $115 from $110 and keeps an Outperform rating on the shares. The analyst notes that the company reported strong Q3 financial results and provided the Street with program updates. Based on Ultragenyx's commercial business that is steadily growing and a flurry of pipeline activities, Schwartz is increasingly optimistic that Ultragenyx may be able to approach its $1B sales goal by 2025.
Ultragenyx price target raised to $110 from $88 at Truist » 08:3010/2810/28/20
Truist analyst Joon Lee…
Truist analyst Joon Lee raised the firm's price target on Ultragenyx to $110 from $88 and keeps a Buy rating on the shares. The analyst cites the company's better than expected Q3 results and points to its "solid" commercial execution. Lee adds that the new commercial strategy adapted by Ultragenyx management for the pandemic "is working."
Ultragenyx files to sell $400M in common stock » 08:0110/2810/28/20
J.P. Morgan, Goldman…
J.P. Morgan, Goldman Sachs & Co. LLC, BofA Securities and Cowen are acting as joint book-running managers for the offering.
Ultragenyx price target raised to $121 from $99 at Barclays » 06:3010/2810/28/20
Barclays analyst Gena…
Barclays analyst Gena Wang raised the firm's price target on Ultragenyx Pharmaceutical to $121 from $99 and reiterates an Overweight rating on the shares following the company's Q3 results. Despite the recent rally in the shares, the analyst continues to see "significant upside" with three approved drugs providing near-term revenue growth and "multiple" pipeline updates to provide near- and long-term upside.